Medwave seeks buyer
This article was originally published in The Gray Sheet
Maker of non-invasive blood pressure measurement and monitoring systems is exploring "strategic alternatives," including the possible sale of the company, Medwave says April 10. The firm disclosed in its recent annual report that continued net losses and an accumulated deficit of about $34 million "raise substantial doubt about the company's ability to continue as a going concern." In January, Medwave received a delisting warning from the Nasdaq stock market when its share price traded below $1 for more than 30 days in a row...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.